Hoffmann A T, Dillenhöfer S, Lücke T, Maier C, Brinkmann F
Universitätsklinik für Kinder- und Jugendmedizin, Ruhr-Universität Bochum, Alexandrinenstraße 5, 44791, Bochum, Deutschland.
Schmerz. 2022 Dec;36(6):422-428. doi: 10.1007/s00482-021-00603-z. Epub 2021 Nov 11.
Cystic fibrosis (CF) is a rare genetic multisystemic disorder with progressive abdominal and pulmonary involvement. Pain is still an underestimated symptom in CF patients.
A comprehensive review of guidelines and scientific literature on the topic was performed and combined with findings from pain management in a young CF patient with progressive thoracic pain.
German CF guidelines do not cover diagnosis and management of pain in these patients. Studies from Europe and the United States report interactions between intensity of pain and mortality in CF, but do not include data on the efficacy of pain management. These data and clinical observations of a CF patient with episodes of intense thoracic pain are used to illustrate the specific challenges in pain relief.
Pain management in CF requires meticulous monitoring as well as an interdisciplinary approach and should be implemented in the German CF guidelines. The authors also want to suggest recommendations for the treatment of thoracic pain in CF. The range and severity of organ involvement complicates the use both of opioids and non-opioids. Especially opioid treatment carries the risk of hypoxia and opioid-induced constipation (OIC) and needs close medical supervision.
囊性纤维化(CF)是一种罕见的遗传性多系统疾病,会逐渐累及腹部和肺部。疼痛在CF患者中仍是一种未得到充分重视的症状。
对该主题的指南和科学文献进行了全面回顾,并结合了一名患有进行性胸痛的年轻CF患者的疼痛管理结果。
德国CF指南未涵盖这些患者疼痛的诊断和管理。欧洲和美国的研究报告了CF患者疼痛强度与死亡率之间的相互关系,但未包括疼痛管理疗效的数据。这些数据以及一名患有剧烈胸痛发作的CF患者的临床观察结果被用于说明疼痛缓解方面的具体挑战。
CF患者的疼痛管理需要细致监测以及多学科方法,应在德国CF指南中实施。作者还想为CF患者胸痛的治疗提出建议。器官受累的范围和严重程度使阿片类药物和非阿片类药物的使用都变得复杂。尤其是阿片类药物治疗存在缺氧和阿片类药物引起的便秘(OIC)风险,需要密切的医疗监督。